The Biggest Drug Dealers Have Always Worn Suits

Key Takeaways

• Purdue Pharma will dissolve; new entity Knoa Pharma will assume assets.
• Sackler family owes up to $7 billion, paid from future earnings.
• Victims may receive $8,000‑$16,000 per claim for historic prescriptions.
• Sacklers retain international opioid sales through Mundipharma in Asia, Latin America.
• No individual executives face criminal charges despite 900,000 opioid deaths.

Pulse Analysis

The court‑approved bankruptcy plan for Purdue Pharma marks a watershed moment in the U.S. opioid saga. By dissolving the company and creating Knoa Pharma, the settlement aims to channel future earnings into a $7 billion fund, while offering modest payouts to thousands of claimants. However, the arrangement sidesteps direct criminal liability for the Sackler executives who steered OxyContin’s aggressive marketing, effectively converting corporate punishment into a financial transaction that preserves the family’s wealth.

Beyond the courtroom, the decision does little to stem the broader public‑health crisis. While American victims may receive limited compensation, the Sacklers continue to profit from OxyContin sales overseas through their Mundipharma network, targeting markets in China, India, Latin America and the Middle East. This mirrors a historical pattern where powerful drug firms rebrand and relocate to evade accountability, leaving communities worldwide to bear the health and social costs of addiction. The settlement therefore raises questions about the adequacy of current legal tools to address transnational pharmaceutical misconduct.

Policymakers and regulators are now faced with a stark choice: tighten bankruptcy provisions to prevent corporate shields, or pursue new avenues for individual accountability, such as civil suits and criminal investigations. The Purdue case underscores the need for stronger oversight of drug marketing, transparent reporting of adverse outcomes, and mechanisms that ensure victims receive meaningful redress. As the opioid epidemic evolves, the industry’s ability to reinvent itself without substantive consequences threatens to perpetuate cycles of addiction and loss.